Fig. 3

Validation of IL1RAP as a NKt-AML antigen. A IL1RAP protein intensity measured by surface proteomics across all AML subgroups of the Leucegene AML surfaceome cohort (n = 100). B IL1RAP transcript levels measured by RNA sequencing across all AML subgroups of the Leucegene AML RNA-sequencing cohort (n = 691). C Single-cell RNA expression of candidate antigens and ADGRG1 in normal BM and AML specimens of the Leucegene AML single-cell RNA-sequencing cohort (n = 20) in all AML cells (HSC: -) or HSC-like AML cells (HSC: +). The percentage of gene-expressing cells along with Z-scores calculated per gene for expression in the different AML subgroups and normal BM are shown. D Validation of IL1RAP cell surface expression in primary human AML specimens by flow cytometry. Left) Distribution of AML subgroups within the cohort of primary human AML specimens analyzed by flow cytometry. Middle) Percentage of IL1RAP-expressing blasts in specimens of indicated AML subgroups. P values were calculated using the Wilcoxon test. Right) Flow cytometry analysis of IL1RAP expression in NKt-AML specimens. Profile from 1 representative specimen is shown